HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression

The HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 haplotype is linked to protection from the development of type 1 diabetes (T1D). However, it is not known at which stages in the natural history of T1D development this haplotype affords protection. We examined a cohort of 3,358 autoantibody-positive relatives of T1D patients in the Pathway to Prevention (PTP) Study of the Type 1 Diabetes TrialNet. The PTP study examines risk factors for T1D and disease progression in relatives. HLA typing revealed that 155 relatives carried this protective haplotype. A comparison with 60 autoantibody-negative relatives suggested protection from autoantibody development. Moreover, the relatives with DRB1*15:01-DQA1*01:02-DQB1*06:02 less frequently expressed autoantibodies associated with higher T1D risk, were less likely to have multiple autoantibodies at baseline, and rarely converted from single to multiple autoantibody positivity on follow-up. These relatives also had lower frequencies of metabolic abnormalities at baseline and exhibited no overall metabolic worsening on follow-up. Ultimately, they had a very low 5-year cumulative incidence of T1D. In conclusion, the protective influence of DRB1*15:01-DQA1*01:02-DQB1*06:02 spans from autoantibody development through all stages of progression, and relatives with this allele only rarely develop T1D.

[1]  BOULIN,et al.  Classification and Diagnosis of Diabetes. , 2022, Primary care.

[2]  Å. Lernmark,et al.  Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association , 2015, Diabetes Care.

[3]  P. Bingley,et al.  Reactivity to N-Terminally Truncated GAD65(96–585) Identifies GAD Autoantibodies That Are More Closely Associated With Diabetes Progression in Relatives of Patients With Type 1 Diabetes , 2015, Diabetes.

[4]  P. Mueller,et al.  Detection of Antibodies Directed to the N-Terminal Region of GAD Is Dependent on Assay Format and Contributes to Differences in the Specificity of GAD Autoantibody Assays for Type 1 Diabetes , 2015, Diabetes.

[5]  J. Krischer,et al.  The Development and Utility of a Novel Scale That Quantifies the Glycemic Progression Toward Type 1 Diabetes Over 6 Months , 2015, Diabetes Care.

[6]  Zhangli,et al.  Electrochemiluminescence assays for insulin and glutamic acid decarboxylase autoantibodies improve prediction of type 1 diabetes risk. , 2015 .

[7]  Å. Lernmark,et al.  Cell-surface MHC density profiling reveals instability of autoimmunity-associated HLA. , 2015, The Journal of clinical investigation.

[8]  M. Rewers,et al.  GAD65 Autoantibodies Detected by Electrochemiluminescence Assay Identify High Risk for Type 1 Diabetes , 2013, Diabetes.

[9]  E. Bonifacio,et al.  Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. , 2013, JAMA.

[10]  A. Steck,et al.  Proinsulin/Insulin Autoantibodies Measured With Electrochemiluminescent Assay Are the Earliest Indicator of Prediabetic Islet Autoimmunity , 2013, Diabetes Care.

[11]  A. Pugliese.  The multiple origins of Type 1 diabetes , 2013, Diabetic medicine : a journal of the British Diabetic Association.

[12]  P. Bingley,et al.  Zinc Transporter-8 Autoantibodies Improve Prediction of Type 1 Diabetes in Relatives Positive for the Standard Biochemical Autoantibodies , 2012, Diabetes Care.

[13]  K. Vehik,et al.  Development of Autoantibodies in the TrialNet Natural History Study , 2011, Diabetes Care.

[14]  B. Roep,et al.  Functional consequences of HLA-DQ8 homozygosity versus heterozygosity for islet autoimmunity in type 1 diabetes , 2011, Genes and Immunity.

[15]  P. Bingley,et al.  Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. , 2010, The Journal of clinical endocrinology and metabolism.

[16]  J. Krischer,et al.  Trends of Earlier and Later Responses of C-peptide to Oral Glucose Challenges With Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants , 2009, Diabetes Care.

[17]  S. Cole,et al.  Overadjustment Bias and Unnecessary Adjustment in Epidemiologic Studies , 2009, Epidemiology.

[18]  P. Bingley,et al.  The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results , 2009, Pediatric diabetes.

[19]  Marian Rewers,et al.  The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes , 2007, Proceedings of the National Academy of Sciences.

[20]  J. Palmer,et al.  T-Cell Responses to Islet Antigens Improves Detection of Autoimmune Diabetes and Identifies Patients With More Severe β-Cell Lesions in Phenotypic Type 2 Diabetes , 2007, Diabetes.

[21]  J. Krischer,et al.  Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes. , 2006, The Journal of clinical endocrinology and metabolism.

[22]  Å. Lernmark,et al.  D6S265*15 marks a DRB1*15, DQB1*0602 haplotype associated with attenuated protection from type 1 diabetes mellitus , 2005, Diabetologia.

[23]  E. Thorsby,et al.  HLA associated genetic predisposition to autoimmune diseases: Genes involved and possible mechanisms. , 2005, Transplant immunology.

[24]  H. Erlich,et al.  Ethnic Differences in the Associations between the HLA‐DRB1*04 Subtypes and Type 1 Diabetes , 2003, Annals of the New York Academy of Sciences.

[25]  M. Peakman,et al.  Promiscuous binding of proinsulin peptides to Type 1 diabetes-permissive and -protective HLA class II molecules , 2003, Diabetologia.

[26]  Andrew W. Liu,et al.  Mutational analysis of critical residues determining antigen presentation and activation of HLA-DQ0602 restricted T-cell clones. , 2002, Human immunology.

[27]  E. Thorsby,et al.  DR- and DQ-associated protection from type 1A diabetes: comparison of DRB1*1401 and DQA1*0102-DQB1*0602*. , 2000, The Journal of clinical endocrinology and metabolism.

[28]  G. Eisenbarth,et al.  Islet cell antibody-positive relatives with human leukocyte antigen DQA1*0102, DQB1*0602: identification by the Diabetes Prevention Trial-type 1. , 2000, The Journal of clinical endocrinology and metabolism.

[29]  P. van Endert,et al.  Identification of peptides from autoantigens GAD65 and IA-2 that bind to HLA class II molecules predisposing to or protecting from type 1 diabetes. , 1999, Diabetes.

[30]  H. Erlich,et al.  Sequence analysis of the diabetes-protective human leukocyte antigen-DQB1*0602 allele in unaffected, islet cell antibody-positive first degree relatives and in rare patients with type 1 diabetes. , 1999, The Journal of clinical endocrinology and metabolism.

[31]  W. Kwok,et al.  A peptide binding motif for HLA-DQA1*0102/DQB1*0602, the class II MHC molecule associated with dominant protection in insulin-dependent diabetes mellitus. , 1998, Journal of immunology.

[32]  A. Pugliese.  Genetic protection from insulin-dependent diabetes mellitus , 1997 .

[33]  P. Santamaria,et al.  A Mechanism for the Major Histocompatibility Complex–linked Resistance to Autoimmunity , 1997, The Journal of experimental medicine.

[34]  J. Todd.  Genetics of type 1 diabetes. , 1997, Pathologie-biologie.

[35]  M. Hoover,et al.  Molecular Modelling of HLA‐DQ Suggests a Mechanism of Resistance in Type 1 Diabetes , 1997, Scandinavian journal of immunology.

[36]  G. Eisenbarth,et al.  Limited loss of tolerance to islet autoantigens in ICA+ first degree relatives of patients with type I diabetes expressing the HLA dqb1*0602 allele. , 1996, Journal of autoimmunity.

[37]  H. Erlich,et al.  HLA-DQB1*0602 Is Associated With Dominant Protection From Diabetes Even Among Islet Cell Antibody–Positive First-Degree Relatives of Patients with IDDM , 1995, Diabetes.

[38]  D. Mathis,et al.  Determinant capture as a possible mechanism of protection afforded by major histocompatibility complex class II molecules in autoimmune disease , 1993, The Journal of experimental medicine.

[39]  L. Nisticò,et al.  An Explanation for the Neutral Effect of DR2 on IDDM Susceptibility in Central Italy , 1992, Diabetes.

[40]  B. Mach,et al.  Extensive study of DRB, DQA, and DQB gene polymorphism in 23 DR2-positive, insulin-dependent diabetes mellitus patients. , 1992, Human immunology.

[41]  H. Erlich,et al.  Implication of Specific DQB1 Alleles in Genetic Susceptibility and Resistance by Identification of IDDM Siblings With Novel HLA-DQB1 Allele and Unusual DR2 and DR1 Haplotypes , 1991, Diabetes.

[42]  J. D. Capra,et al.  Analysis of HLA-DQ genotypes and susceptibility in insulin-dependent diabetes mellitus. , 1990, The New England journal of medicine.

[43]  J. Trowsdale,et al.  Major histocompatibility complex structure and function. , 1989, Current opinion in immunology.

[44]  J. Todd,et al.  Aspartic acid at position 57 of the HLA-DQ beta chain protects against type I diabetes: a family study. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[45]  M. Rewers,et al.  Electrochemiluminescence assays for insulin and glutamic acid decarboxylase autoantibodies improve prediction of type 1 diabetes risk. , 2015, Diabetes technology & therapeutics.

[46]  H. Erlich,et al.  Implication of Specific DQB 1 Alleles in Genetic Susceptibility and Resistance by Identification of IDDM Siblings With Novel HLA-DQB 1 Allele and Unusual DR 2 and DR 1 Haplotypes , 2010 .

[47]  J. Palmer,et al.  T-cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe beta-cell lesions in phenotypic type 2 diabetes. , 2007, Diabetes.

[48]  D. Power.  Standards of medical care in diabetes. , 2006, Diabetes care.

[49]  C. Carcassi,et al.  A new HLA-DR2 extended haplotype is involved in insulin-dependent diabetes mellitus susceptibility. , 1991, Human immunology.

[50]  J. Todd,et al.  HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. , 1987, Nature.